Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hafnium oxide - Nanobiotix

Next Previous
Drug Profile

Hafnium oxide - Nanobiotix

Alternative Names: Hafnium Oxide nanoparticles; JNJ-1900; JNJ-90301900; NBTX 3; NBTXR-3; PEP-503

Latest Information Update: 03 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanobiotix
  • Developer Janssen Pharmaceutica; LianBio; M. D. Anderson Cancer Center; Nanobiotix; National Cancer Institute (USA); PharmaEngine; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Radiosensitisers; Small molecules
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Squamous cell cancer
  • Phase II/III Soft tissue sarcoma
  • Phase II Non-small cell lung cancer
  • Phase I/II Liver cancer; Rectal cancer; Solid tumours
  • Phase I Adenocarcinoma; Oesophageal cancer
  • Suspended Prostate cancer

Most Recent Events

  • 20 Mar 2026 Nanobiotix, in collaboration with the University of Texas MD Anderson Cancer Center suspends a phase I trial in Adenocarcinoma (Late-stage disease, Metastatic disease, Combination therapy) in USA (Intratumoural), due to principal investigator's request (NCT04484909)
  • 23 Jan 2026 M.D. Anderson Cancer Center terminates a phase-II trial in Squamous cell cancer (Recurrent, Second-line therapy or greater, Metastatic disease, Combination therapy) in USA (Intralymphatic, Intratumoural) due to less than 75% participation (NCT04862455)
  • 11 Dec 2025 Phase-I clinical trials in Squamous cell cancer (Late-stage disease, Combination therapy) in USA (Intralymphatic) (NCT07219212)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top